Riskpilot← Back to searchSign inGet full accessRechon Life Science AB
ABActiveOrg 5567139992Soldattorpsvägen 5Manufacture of pharmaceutical preparations · NACE 2120Est. 2006286 employees
Revenue 2024
SEK 557,6M
+15% vs 2023
EBITDA margin
14.7%
+4% vs 2023
Equity ratio
32.0%
Financial strength
Net profit 2024
SEK 39,1M
+29% vs 2023
| Revenue | SEK 557,6M | +15% |
| EBITDA | SEK 81,9M | +4% |
| Net profit | SEK 39,1M | +29% |
| Total assets | SEK 486,4M | +34% |
| Equity | SEK 155,8M | +34% |
| Employees | 286 | — |
Legal name
Rechon Life Science AB
Org number
5567139992
Legal form
Aktiebolag
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
27 oktober 2006
Share capital
SEK 27 541 000
Employees
286 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas ensam av Li, Zhaoqi Dessutom har verkställande direktören rätt att teckna firmanbeträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska tillverka läkemedel samt bedriva därmed förenlig verksamhet.
Address
Soldattorpsvägen 5
Phone
+4640361010
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 306 969 | 305 650 | 388 250 | 485 933 | 557 628 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 37 567 | 43 255 | 77 836 | 78 704 | 81 860 |
| Depreciation & amort. | −9 763 | −12 941 | −16 286 | −19 145 | −18 751 |
| EBIT | 27 804 | 30 314 | 61 550 | 59 559 | 63 109 |
| Net financials | −769 | −1 052 | −1 296 | −3 130 | −3 943 |
| Profit before tax | 17 583 | 18 871 | 35 415 | 38 477 | 49 720 |
| Tax | −3 832 | −3 978 | −5 243 | −8 195 | −10 602 |
| Net profit | 13 751 | 14 893 | 30 172 | 30 282 | 39 118 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 217 546 | 283 668 | 326 949 | 364 324 | 486 410 |
| Equity | 72 596 | 77 863 | 97 351 | 116 640 | 155 758 |
| Long-term debt | 27 913 | 84 742 | 57 062 | 36 137 | 66 849 |
| Short-term debt | 59 551 | 53 186 | 79 819 | 100 878 | 143 689 |
| Total debt | 87 464 | 137 928 | 136 881 | 137 015 | 210 538 |
EBITDA margin
14.7%
This company
15.8%
Market median
-7% vs market
20202024
Equity ratio
32.0%
This company
38.2%
Market median
+16% vs market
20202024
Return on equity
25.1%
This company
18.4%
Market median
+36% vs market
20202024
Net profit margin
7.0%
This company
8.1%
Market median
-14% vs market
20202024
Asset turnover
1.15×
This company
1.12×
Market median
+3% vs market
20202024
Debt / equity
2.12×
This company
0.62×
Market median
-242% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
MC Chief Auditor | Chief Auditor | 2022 |
RP Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2022 | |
| Deputy Board Member | 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
SHANGHAI DONGBAO BIOPHARMACEUTICALS CO., LTD
Rechon Life Science AB (this company)Board members of Rechon Life Science AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Mona Christina Nilsson | Chief Auditor | 0 companies |
| Roland Patrik Holmqvist | Chief Executive Officer | 0 companies |
| Zhaoqi Li | Chairman | 0 companies |
| Christina Ulrika Jonius Aston | Deputy Board Member | 0 companies |